Clinical-stage neurology biotech with 4 Phase 2 programs licensed from Eisai and Jiangsu Hansoh; TRTL-107 schizophrenia, GABA modulator tinnitus, GAT-1 epilepsy, PDE9 encephalopathies
No detailed funding rounds available.
Total known funding: